Kathryn E. Haley

Kathryn E. Haley

Auto-generated profile, based on publicly available information

Kathryn E. Haley

Graduate Entry Medicine, RCSI University of Medicine and Health Sciences, Dublin 2 Dublin, Ireland; Tissue Engineering Research Group (TERG), Department of Anatomy and Regenerative Medicine, RCSI University of Medicine and Health Sciences, Dublin 2 Dublin, Ireland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
CDCatríona M. Dowling
Catríona M. Dowling
KHKate E. R. Hollinshead
Kate E. R. Hollinshead
AGAlessandra Di Grande
Alessandra Di Grande
JPJustin Pritchard
Justin Pritchard
HZHua Zhang
Hua Zhang
TCTríona Ní Chonghaile
Tríona Ní Chonghaile
Discovery of a new HDAC6 inhibitor reveals role for HDAC6 in the regulation of glycolytic metabolism.

1 June 2018 in Science Advances
Verified
Journal Article
Open access
PDF file
KHKathryn E. Haley
Kathryn E. Haley
NKNils Kronenberg
Nils Kronenberg
PLPhilipp Liehm
Philipp Liehm
MEMustafa Elshani
Mustafa Elshani
CBCameron Bell
Cameron Bell
PRPaul Reynolds
Paul Reynolds
ERISM continuously maps dynamic changes in the forces podocytes exert on their substrate in a model of acute kidney damage.

1 October 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
KHKathryn E. Haley
Kathryn E. Haley
TATalal Almas
Talal Almas
SSSaeed Shoar
Saeed Shoar
SSShan Shaikh
Shan Shaikh
MAMaimoona Azhar
Maimoona Azhar
AHAamir Hameed
Aamir Hameed
Ongoing advancements in the treatment of acute myocardial infarction (MI) have significantly decreased MI related mortality. Consequently, the number of patients experiencing post-MI heart failure (HF) has continued to rise. Infarction size and the extent of left ventricular (LV) remodeling are largely determined by the extent of ischemia at the time of myocardial injury. In the setting of MI or acute phase of post-MI LV remodeling, anti-inflammatory drugs including intravenous immunoglobulin (IVIG) and Pentoxifylline have shown potential efficacy in preventing post-MI remodeling in-vitro and in some clinical trials. However, systemic administration of anti-inflammatory drugs are not without their off-target side effects. Herein, we explore the clinical feasibility of targeted myocardial delivery of anti-inflammatory drugs via biodegradable polymers, liposomes, hydrogels, and nano-particle based drug delivery models (NDDM) based on existing pre-clinical and clinical models. We summarize the barriers to clinical application of targeted anti-inflammatory delivery post-MI, including challenges in achieving sufficient retention and distribution, as well as the potential need for multiple dosing. Collectively, we suggest that localized delivery of anti-inflammatory agents to the myocardium using NDDM is a promising approach for successful treatment of ischemic HF. Future studies will be instrumental in determining the most effective target and delivery modalities for orchestrating NDDM-mediated treatment of HF.

1 December 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
LWLouise Walsh
Louise Walsh
KHKathryn E. Haley
Kathryn E. Haley
BMBruce Moran
Bruce Moran
BMBrian Mooney
Brian Mooney
FTFinbarr Tarrant
Finbarr Tarrant
TCTríona Ní Chonghaile
Tríona Ní Chonghaile
Purpose: Invasive lobular carcinoma (ILC) is a subtype of breast cancer accounting for 10% of breast tumors. The majority of patients are treated with endocrine therapy; however, endocrine resistance is common in estrogen receptor–positive breast cancer and new therapeutic strategies are needed. Bromodomain and extraterminal inhibitors (BETi) are effective in diverse types of breast cancer but they have not yet been assessed in ILC. Experimental Design: We assessed whether targeting the BET proteins with JQ1 could serve as an effective therapeutic strategy in ILC in both 2D and 3D models. We used dynamic BH3 profiling and RNA-sequencing (RNA-seq) to identify transcriptional reprograming enabling resistance to JQ1-induced apoptosis. As part of the RATHER study, we obtained copy-number alterations and RNA-seq on 61 ILC patient samples. Results: Certain ILC cell lines were sensitive to JQ1, while others were intrinsically resistant to JQ1-induced apoptosis. JQ1 treatment led to an enhanced dependence on antiapoptotic proteins and a transcriptional rewiring inducing fibroblast growth factor receptor 1 (FGFR1). This increase in FGFR1 was also evident in invasive ductal carcinoma (IDC) cell lines. The combination of JQ1 and FGFR1 inhibitors was highly effective at inhibiting growth in both 2D and 3D models of ILC and IDC. Interestingly, we found in the RATHER cohort of 61 ILC patients that 20% had FGFR1 amplification and we showed that high BRD3 mRNA expression was associated with poor survival specifically in ILC. Conclusions: We provide evidence that BETi either alone or in combination with FGFR1 inhibitors or BH3 mimetics may be a useful therapeutic strategy for recurrent ILC patients.

31 March 2023
Verified
Other
Open access
LWLouise Walsh
Louise Walsh
KHKathryn E. Haley
Kathryn E. Haley
BMBruce Moran
Bruce Moran
BMBrian Mooney
Brian Mooney
FTFinbarr Tarrant
Finbarr Tarrant
TCTríona Ní Chonghaile
Tríona Ní Chonghaile

31 March 2023
Verified
Other
Open access
LWLouise Walsh
Louise Walsh
KHKathryn E. Haley
Kathryn E. Haley
BMBruce Moran
Bruce Moran
BMBrian Mooney
Brian Mooney
FTFinbarr Tarrant
Finbarr Tarrant
TCTríona Ní Chonghaile
Tríona Ní Chonghaile
Table S3: Cox regression analysis on RATHER RNA-seq data